BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 17621726)

  • 1. Prevalence of BRCA1 expression in epithelial ovarian cancer: immunohistochemical study.
    Sirisabya N; Manchana T; Termrungreunglert W; Triratanachat S; Charuruks N; Tresukosol D
    J Med Assoc Thai; 2007 Jan; 90(1):9-14. PubMed ID: 17621726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
    Tan DS; Rothermundt C; Thomas K; Bancroft E; Eeles R; Shanley S; Ardern-Jones A; Norman A; Kaye SB; Gore ME
    J Clin Oncol; 2008 Dec; 26(34):5530-6. PubMed ID: 18955455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients.
    Wang L; Madigan MC; Chen H; Liu F; Patterson KI; Beretov J; O'Brien PM; Li Y
    Gynecol Oncol; 2009 Aug; 114(2):265-72. PubMed ID: 19450871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.
    Chetrit A; Hirsh-Yechezkel G; Ben-David Y; Lubin F; Friedman E; Sadetzki S
    J Clin Oncol; 2008 Jan; 26(1):20-5. PubMed ID: 18165636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer.
    Hylander B; Repasky E; Shrikant P; Intengan M; Beck A; Driscoll D; Singhal P; Lele S; Odunsi K
    Gynecol Oncol; 2006 Apr; 101(1):12-7. PubMed ID: 16263157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FISH analysis of BRCA1 copy number in paraffin-embedded ovarian cancer tissue samples.
    Kato H; Arakawa A; Suzumori K; Kataoka N; Young SR
    Exp Mol Pathol; 2004 Apr; 76(2):138-42. PubMed ID: 15010292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of ovarian cancer patients who underwent incomplete surgical staging.
    Panprom P; Lertkhachonsuk R
    J Med Assoc Thai; 2008 Sep; 91(9):1323-30. PubMed ID: 18843859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specialized care and survival of ovarian cancer patients in The Netherlands: nationwide cohort study.
    Vernooij F; Heintz AP; Witteveen PO; van der Heiden-van der Loo M; Coebergh JW; van der Graaf Y
    J Natl Cancer Inst; 2008 Mar; 100(6):399-406. PubMed ID: 18334710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of androgen receptor cytosine-adenine-guanine polymorphisms on clinical outcome in BRCA mutation-associated epithelial ovarian cancers.
    Li AJ; McAllister P; Karlan BY
    Gynecol Oncol; 2010 Jan; 116(1):105-8. PubMed ID: 19818997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between the N-terminally truncated (DeltaN) p63alpha (DeltaNp63alpha) isoform and debulking status, VEGF expression and progression-free survival in previously untreated, advanced stage epithelial ovarian cancer: A Gynecologic Oncology Group study.
    Jewell EL; Darcy KM; Hutson A; Lee PS; Havrilesky LJ; Grace LA; Berchuck A; Secord AA
    Gynecol Oncol; 2009 Dec; 115(3):424-9. PubMed ID: 19767063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of cathepsin B expression may offer additional prognostic information for ovarian cancer patients.
    Scorilas A; Fotiou S; Tsiambas E; Yotis J; Kotsiandri F; Sameni M; Sloane BF; Talieri M
    Biol Chem; 2002; 383(7-8):1297-303. PubMed ID: 12437120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study.
    Schilder RJ; Sill MW; Lee RB; Shaw TJ; Senterman MK; Klein-Szanto AJ; Miner Z; Vanderhyden BC
    J Clin Oncol; 2008 Jul; 26(20):3418-25. PubMed ID: 18612157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland.
    Brozek I; Ochman K; Debniak J; Morzuch L; Ratajska M; Stepnowska M; Stukan M; Emerich J; Limon J
    Gynecol Oncol; 2008 Feb; 108(2):433-7. PubMed ID: 17997147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gamma-knife radiosurgery as an optimal treatment modality for brain metastases from epithelial ovarian cancer.
    Lee YK; Park NH; Kim JW; Song YS; Kang SB; Lee HP
    Gynecol Oncol; 2008 Mar; 108(3):505-9. PubMed ID: 18191184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer.
    Spentzos D; Cannistra SA; Grall F; Levine DA; Pillay K; Libermann TA; Mantzoros CS
    Endocr Relat Cancer; 2007 Sep; 14(3):781-90. PubMed ID: 17914107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients.
    Mezzanzanica D; Fabbi M; Bagnoli M; Staurengo S; Losa M; Balladore E; Alberti P; Lusa L; Ditto A; Ferrini S; Pierotti MA; Barbareschi M; Pilotti S; Canevari S
    Clin Cancer Res; 2008 Mar; 14(6):1726-33. PubMed ID: 18347173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The transcription factor Sox11 is a prognostic factor for improved recurrence-free survival in epithelial ovarian cancer.
    Brennan DJ; Ek S; Doyle E; Drew T; Foley M; Flannelly G; O'Connor DP; Gallagher WM; Kilpinen S; Kallioniemi OP; Jirstrom K; O'Herlihy C; Borrebaeck CA
    Eur J Cancer; 2009 May; 45(8):1510-7. PubMed ID: 19272768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and amplification of eIF-5A2 in human epithelial ovarian tumors and overexpression of EIF-5A2 is a new independent predictor of outcome in patients with ovarian carcinoma.
    Yang GF; Xie D; Liu JH; Luo JH; Li LJ; Hua WF; Wu HM; Kung HF; Zeng YX; Guan XY
    Gynecol Oncol; 2009 Feb; 112(2):314-8. PubMed ID: 19054548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased staining for phosphorylated AKT and nuclear factor-kappaB p65 and their relationship with prognosis in epithelial ovarian cancer.
    Guo RX; Qiao YH; Zhou Y; Li LX; Shi HR; Chen KS
    Pathol Int; 2008 Dec; 58(12):749-56. PubMed ID: 19067848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.